Back to Search Start Over

Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population

Authors :
Amir A. Kuperman
Tracie A. Goldberg
Carina Levin
Hannah Tamary
Orly Dgany
Tanya Krasnov
Orna Steinberg-Shemer
Joseph Kapelushnik
Hagit Miskin
Vered Shkalim Zemer
Ariel Koren
Ayelet Ben-Barak
Tal Ben-Ami
Sharon Noy-Lotan
Joanne Yacobovich
Shoshana Revel-Vilk
Amos Toren
Source :
Haematologica
Publication Year :
2019
Publisher :
Ferrata Storti Foundation (Haematologica), 2019.

Abstract

Fanconi anemia (FA), an inherited bone marrow failure (BMF) syndrome, caused by mutations in DNA repair genes, is characterized by congenital anomalies, aplastic anemia, high risk of malignancies and extreme sensitivity to alkylating agents. We aimed to study the clinical presentation, molecular diagnosis and genotype-phenotype correlation among patients with FA from the Israeli inherited BMF registry. Overall, 111 patients of Arab (57%) and Jewish (43%) descent were followed for a median of 15 years (range: 0.1-49); 63% were offspring of consanguineous parents. One-hundred patients (90%) had at least one congenital anomaly; over 80% of the patients developed bone marrow failure; 53% underwent hematopoietic stem-cell transplantation; 33% of the patients developed cancer; no significant association was found between hematopoietic stem-cell transplant and solid tumor development. Nearly 95% of the patients tested had confirmed mutations in the Fanconi genes FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%), including twenty novel mutations. Patients with FANCA mutations developed cancer at a significantly older age compared to patients with mutations in other Fanconi genes (mean 18.5 and 5.2 years, respectively, P=0.001); however, the overall survival did not depend on the causative gene. We hereby describe a large national cohort of patients with FA, the vast majority genetically diagnosed. Our results suggest an older age for cancer development in patients with FANCA mutations and no increased incidence of solid tumors following hematopoietic stem-cell transplant. Further studies are needed to guide individual treatment and follow-up programs.

Details

ISSN :
15928721 and 03906078
Volume :
105
Database :
OpenAIRE
Journal :
Haematologica
Accession number :
edsair.doi.dedup.....96a3f37a4c55fac889e18c424d8d6aef
Full Text :
https://doi.org/10.3324/haematol.2019.222877